search
Back to results

The Genetics of Environmental Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
LPS endotoxin, saline, HDM
Sponsored by
National Institute of Environmental Health Sciences (NIEHS)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Asthma focused on measuring Genetics, Lipopolysaccharide

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Atopic/asthmatic, atopic/non-asthmatic, non-atopic/asthmatic, or non-atopic/non-asthmatic Asthma subjects will be required to have either mild or moderate persistent asthma; positive methacholine challenge Atopic subjects should have seasonal allergy symptoms requiring medication and have positive skin test to house dust mite and at least 3 additional allergens. Serum IgE level >100. Willing/able to give informed consent & adhere to visit/protocol schedules. Screening visit laboratory, C-Xray, EKG, results within normal limits Women of childbearing potential must have a negative serum pregnancy test Screening Pulmonary Function testing above study criteria parameters Exclusion Criteria: Systemic corticosteroid administration for asthma within the previous 90days Antibiotic administration within the previous 30 days. Viral respiratory infection within the previous 14 days. History of severe asthma requiring intubation. Occupational exposure to hay or grain dust. Significant exposure history to cigarette smoke Past or present history of allergen immunotherapy Underlying illnesses that may result in altered lung function Students or employees under direct supervision by protocol investigators are ineligible Subjects allergic to medications used (or potentially used) in the study will be excluded. Subjects using aspirin will be excluded Subjects who abuse alcohol or illicit substances will be excluded Medication use other than for asthma, allergies or contraception Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements Nursing mothers Other investigational medication within the last 30 days

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

bronchoscopy

Arm Description

2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.

Outcomes

Primary Outcome Measures

BAL and endobronchial brush biopsy are measured and cell samples are analyzed to identify the genes in airway epithelia and inflammatory cells that are differentially expressed in response to LPS and dust mite antigen.RNA is isolated for gene expression.

Secondary Outcome Measures

post bronchoscopy symptom followup

Full Information

First Posted
July 2, 2001
Last Updated
May 5, 2008
Sponsor
National Institute of Environmental Health Sciences (NIEHS)
Collaborators
National Center for Research Resources (NCRR)
search

1. Study Identification

Unique Protocol Identification Number
NCT00018096
Brief Title
The Genetics of Environmental Asthma
Official Title
The Genetics of Environmental Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2008
Overall Recruitment Status
Completed
Study Start Date
June 2001 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Environmental Health Sciences (NIEHS)
Collaborators
National Center for Research Resources (NCRR)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this project, we hypothesize that polymorphisms of genes expressed by the airway epithelia in asthmatics following specific airway challenges predispose individuals to the development of asthma. To test this hypothesis, we identify the genes that are differentially expressed by airway epithelial cells following challenge with stimuli that induce acquired (house dust mite) or innate (LPS) immune responses, and then determine whether polymorphisms in these genes are associated with the development of asthma in a separate, well characterized, familial cohort of asthmatics. This is a powerful approach that is designed to identify novel genes that are associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study).
Detailed Description
The overall goal of this project is to identify genes that are involved in the development of airflow obstruction and airway inflammation in asthmatics, and to determine whether polymorphisms in these differentially expressed genes predispose individuals to develop asthma. Asthma is a complex genetic disorder that is caused by a number of unique gene-gene and gene-environment interactions. The search for asthma susceptibility genes has been complicated by the broad clinical phenotype of asthma, the polygenic inheritance pattern of this disease, and the substantial role of environmental exposures in the development and progression of asthma. Inhaled environmental agents induce several biologic responses in asthmatics; including the induction of acquired and innate immunity that leads to acute and chronic forms of airway inflammation and airway remodeling. Acquired immune responses to protein antigens, such as house dust mite allergen, often induce type 2 T lymphocyte-driven responses (Th2) which appear to be important in atopic asthma. Recent studies by our group and others demonstrate that innate immunity, initiated by inhalation of bacterial and viral pathogens, organic dusts, endotoxin or lipopolysaccharide (LPS), air pollution particulate matter, and ozone, can also cause acute and chronic forms of airflow obstruction, airway inflammation, and even airway remodeling. Emerging evidence indicates that both acquired and innate immune responses in the lung may be influenced by polymorphic genes. For instance, functional polymorphisms in the IL-4 receptor gene are thought to preferentially stimulate acquired Th2 immune responses to inhaled allergens, and we have recently shown that common co-segregating mutations in TLR4 (a transmembrane receptor for LPS) are associated with diminished airway responsiveness to inhaled LPS. These observations suggest that environmental challenges can be used to narrow the phenotype of asthma and investigate genetic susceptibility in biologically specific forms of asthma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Genetics, Lipopolysaccharide

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
176 (Actual)

8. Arms, Groups, and Interventions

Arm Title
bronchoscopy
Arm Type
Experimental
Arm Description
2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
Intervention Type
Biological
Intervention Name(s)
LPS endotoxin, saline, HDM
Other Intervention Name(s)
CCRE lipopolysaccharide endotoxin E.Coli O:113,Lot# 67801, House dust mite allergen (D.farinae) Greer Lab Lot #22574
Intervention Description
instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
Primary Outcome Measure Information:
Title
BAL and endobronchial brush biopsy are measured and cell samples are analyzed to identify the genes in airway epithelia and inflammatory cells that are differentially expressed in response to LPS and dust mite antigen.RNA is isolated for gene expression.
Time Frame
4 hours post first instillation bronchoscopy
Secondary Outcome Measure Information:
Title
post bronchoscopy symptom followup
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Atopic/asthmatic, atopic/non-asthmatic, non-atopic/asthmatic, or non-atopic/non-asthmatic Asthma subjects will be required to have either mild or moderate persistent asthma; positive methacholine challenge Atopic subjects should have seasonal allergy symptoms requiring medication and have positive skin test to house dust mite and at least 3 additional allergens. Serum IgE level >100. Willing/able to give informed consent & adhere to visit/protocol schedules. Screening visit laboratory, C-Xray, EKG, results within normal limits Women of childbearing potential must have a negative serum pregnancy test Screening Pulmonary Function testing above study criteria parameters Exclusion Criteria: Systemic corticosteroid administration for asthma within the previous 90days Antibiotic administration within the previous 30 days. Viral respiratory infection within the previous 14 days. History of severe asthma requiring intubation. Occupational exposure to hay or grain dust. Significant exposure history to cigarette smoke Past or present history of allergen immunotherapy Underlying illnesses that may result in altered lung function Students or employees under direct supervision by protocol investigators are ineligible Subjects allergic to medications used (or potentially used) in the study will be excluded. Subjects using aspirin will be excluded Subjects who abuse alcohol or illicit substances will be excluded Medication use other than for asthma, allergies or contraception Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements Nursing mothers Other investigational medication within the last 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sundy S. Sundy, MD. PhD.
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Genetics of Environmental Asthma

We'll reach out to this number within 24 hrs